chartexchange

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire Inc. | Nov 12, 2026 4:01 PM EST

CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:

Read original article